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Objective: Schizophrenia is a multifactorial disorder. It is known that a combination of extensive
multiple common alleles may be involved in its etiology, each contributing with a small to moderate
effect, and, possibly, some rare alleles with a much larger effect size. We aimed to perform a
systematic review of association studies between schizophrenia (and its subphenotypes) and
polymorphisms in the CNR1 gene, which encodes cannabinoid receptors classically implicated in
schizophrenia pathophysiology, as well as to present unpublished results of an association study in a
Brazilian population.
Methods: Two reviewers independently searched for eligible studies and extracted outcome data
using a structured form. Papers were retrieved from PubMed and ISI Web of Knowledge using the
search term schizophrenia in combination with CNR1 or CB1 or cannabinoid receptor. Twenty-four
articles met our inclusion criteria. We additionally present data from a study of our own comparing 182
patients with schizophrenia and 244 healthy controls.
Results: No consistent evidence is demonstrated.
Conclusion: Some seemingly positive association studies stress the need for further investigations of
the possible role of endocannabinoid genetics in schizophrenia.
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Introduction
Schizophrenia is well known for its heterogeneous clini-
cal symptom dimensions, interindividual variability in phar-
macological treatment response, and the lack of an
established understanding of its pathophysiology. It is a
multifactorial disorder, as a complex interaction of genetic
and environmental factors contribute to its etiology, and
features high heritability (64-83%).1,2 Currently, it is known
that a combination of extensive multiple common alleles -
each one contributing with a small to moderate effect - and,
possibly, some rare alleles with much larger effect size3 are
implicated in schizophrenia. However, despite the progress
achieved in recent years, particularly in genetics and neu-
roimaging, we still have more questions than answers
regarding its causes.
Cannabis exposure, particularly during early adoles-
cence, has long been considered a risk factor for psychosis
and, more recently, for schizophrenia.4,5 However, the
underlying neurobiological mechanisms responsible for this
association are not well understood. Recent research has
pointed toward a complex gene-environment interaction
that involves several variables, such as time of exposure
(usually in early life) and genetic predisposition to psy-
chosis.6 This interaction would lead to disrupted brain
maturation and abnormalities in molecular functioning.
Although dopaminergic and glutamatergic transmis-
sions are the classical neurobiological pathways impli-
cated in the pathophysiology of schizophrenia, the
endocannabinoid system has emerged as a possible link
between cannabis and psychosis.7 This interaction may
consider the effects of exogenous and endogenous canna-
binoid compounds alike on the brain. It is well established
that the psychogenic properties of cannabis are mainly
mediated by delta-9-tetrahydrocannabinol (THC) stimula-
tion of type-1 cannabinoid receptors (CB1).8 CB1 recep-
tor activation may also modulate other pathways, such
as glutamate, dopamine, and gamma-aminobutyric acid
(GABA).9 In addition, some studies have verified abnorm-
alities in endocannabinoid ligands such as anandamide
in patients with schizophrenia,10,11 while others observed
a potential antipsychotic property of CB1 receptor antag-
onists.7,12 Neuroimaging findings have also associa-
ted cannabis use with progressive cortical thickness in
areas rich in CB1 receptors during the initial years of
schizophrenia.13 This body of evidence suggests possible
influences of the endocannabinoid system in the patho-
physiology of the disorder.
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Therefore, considering the involvement of the endo-
cannabinoid system in psychosis and the high heritability
of schizophrenia, the CNR1 gene, which encodes CB1
receptors, has been proposed as one candidate gene
that may contribute to the etiology of schizophrenia and
related phenotypes. CNR1 is located on chromosome
6q14-1514 and is expressed widely in the central nervous
system.15 Polymorphisms in this gene have been asso-
ciated with schizophrenia16 and comorbid substance
abuse,17 as well as with antipsychotic response18 and
adverse effects19; however, other studies have reported
negative findings,20,21 and these associations remain
inconclusive.
Within this context, the aim of the present study was
to conduct a systematic review of all association studies
of the CNR1 gene with schizophrenia and its related
subphenotypes, including clinical response and side
effects of antipsychotic drugs. In addition, we report un-
published results of a comparison of CNR1 gene single
nucleotide polymorphisms (SNPs) in a Brazilian sample of
patients with schizophrenia and healthy controls.
Methods
Association study
This study was approved by the Ethics Committee of
Universidade Federal de São Paulo (UNIFESP; protocol
no. 1737/06). Written informed consent was obtained
from all recruited participants or their caregivers, and all
clinical and laboratory investigations were conducted in
strict accordance with the principles expressed in the
Declaration of Helsinki. All invited subjects agreed to enroll
in this study. A total of 182 patients and 244 healthy
controls were recruited through Programa de Esquizofrenia
(PROESQ) and Laboratório Interdisciplinar de Neurociên-
cias Clı́nicas (LiNC), both at UNIFESP, São Paulo, Brazil.
The diagnosis of schizophrenia was established accord-
ing to the DSM-IV criteria, using the Structured Clinical
Interview of the DSM-IV (SCID). Treatment-resistant (TR)
status was defined in accordance with the International
Psychopharmacological Criteria (IPAP; www.ipap.org) as
failure to respond to 4- to 6-week trials of monotherapy with
two different antipsychotics at adequate doses. Age- and
gender-matched healthy controls with no family history of
psychotic disease were recruited at UNIFESP. These
subjects were also investigated using a modified version
of SCID screening to exclude any with current or previous
psychiatric diagnoses. The descriptive characteristics of
the sample are presented in Table 1. Whole blood was
collected from each subject and DNA was extracted using
a Gentra Puregene kit (Qiagen, Germantown, United Sta-
tes). All four CNR1 SNPs (rs806380, rs806379, rs1049353,
and rs806368) were genotyped by TaqMan probe-based
real-time polymerase chain reaction (PCR) assays (Life
Technologies, Foster City, United States) performed under
standard conditions. For each reaction, at least one positive
control for each genotype was included. Statistical analysis
was based on logistic regression, including group (control
and patient or TR-schizophrenia [TRS] and non-TRS) as
the dependent variable and genotypes, age, gender, and
ethnicity as independent variables.
Systematic review
The PubMed (http://www.ncbi.nlm.nih.gov/pubmed) and
ISI Web of Knowledge (http://apps.webofknowledge.com)
databases were searched from the first date available to
June 2016, using the term schizophrenia in combination
with CNR1 or CB1 or CB1. Two reviewers independently
searched for eligible studies and extracted outcome data
using a structured form designed for this purpose.
On PubMed, the final query resulted the following:
("schizophrenia" [MeSH Terms] OR "schizophrenia" [All
Fields]) AND (CNR1 [All Fields] OR CB1 [All Fields] OR
("receptors, cannabinoid" [MeSH Terms] OR ("receptors"
[All Fields] AND "cannabinoid" [All Fields]) OR "cannabi-
noid receptors" [All Fields] OR ("cannabinoid" [All Fields]
AND "receptor" [All Fields]) OR "cannabinoid receptor"
[All Fields])). On ISI Web of Knowledge the final query
was: (schizophrenia AND (CNR1 or CB1 or cannabinoid
receptor)). The results were downloaded and imported
into EndNote X5 software (Thomson Reuters) to remove
duplicates and select the papers that would be included in
the systematic review.
Genetic analyses of CNR1 polymorphisms with schizo-
phrenia or its subphenotypes as outcomes were eligible
for inclusion. Studies that did not genotype CNR1 poly-
morphisms and did not have schizophrenia or its sub-
phenotypes as outcomes were excluded.
Results
Association study (unpublished data)
The sample is described in Table 1. Our investigation did
not show any significant association between schizo-
phrenia and genotypes (Table 1), nor of TRS with
rs806380 (p = 0.351), rs806379 (p = 0. 050), rs1049353
(p = 0.105), or rs806368 (p = 0.502). After consider-
ing cannabis use (yes/no) as a dependent variable in
the logistic regression, we did not find any positive
association with TRS: rs806380 (p = 0.375), rs806379
(p = 0.086), rs1049353 (p = 0.091), and rs806368
(p = 0.392). When considering frequency of cannabis
use (o 10 times; 10-50 times; 4 50 times) as a depen-
dent variable, no association was found: rs806380
(p = 0.965), rs806379 (p = 0.266), rs1049353 (p = 0.985),
and rs806368 (p = 0.684). We did not evaluate adverse
effects of antipsychotic pharmacological treatment in our
study population. As cannabis use was an exclusion
criterion for the control group, we could not investigate the
effect of genotypes and cannabis use on schizophrenia risk,
although we could assess the influence of these factors on
TRS.
Systematic review
The final flow diagram is presented in Figure 1, and the
selected studies listed in Table 2. A total of 24 studies
involving CNR1 polymorphisms and schizophrenia were
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selected; we divided the results into three sections
according to primary outcome: schizophrenia, substance
abuse comorbidity, and pharmacological treatment.
CNR1 gene polymorphisms and occurrence of
schizophrenia and its symptoms
Studies of genetic variants affecting the CNR1 gene in
different populations showed conflicting results regarding
a possible association with schizophrenia. One of the first
such studies investigated the CNR1 (AAT)n repeat poly-
morphism in Caucasians and did not find evidence for
linkage or association to schizophrenia using 23 multiplex
schizophrenia pedigrees, 131 individuals with the dis-
ease, and 103 controls.22
A few years later, Tsai et al.23 compared the genotype
and allele frequencies of the (AAT)n repeat polymorphism
in 127 patients with schizophrenia and 146 healthy con-
trols from the Han Chinese population. The results indica-
ted no significant association of this polymorphism with
pathogenesis of schizophrenia in that population. Simi-
larly, in a French Caucasian population, no significant
association was found with the (AAT)n repeat in a
comparison of 102 patients with schizophrenia and 89
controls.25
Ujike et al.16 conducted an association study with
Japanese patients with schizophrenia (n=121) and age-
matched healthy controls (n=148). Although the rs1049353
polymorphism was not associated with schizophrenia in
this study, the allelic distributions of the (AAT)n repeat
were significantly different between controls and individuals
with schizophrenia (p = 0.046), especially for hebephrenia
Table 1 Descriptive characteristics of the sample
Variable Patients Controls Statistics
Gender
Male 127 147
Female 55 97 w2 = 4.129; df = 1; p = 0.042












Lifetime frequency of cannabis use
o 10 times 17
10-50 times 9
















TT 107 146 p = 0.701
Data presented as n unless noted otherwise.
w2 = chi-square; df = degrees of freedom; SD = standard deviation; TR = treatment-resistant.
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Figure 1 Flow diagram of the systematic review. CB1 = type 1 cannabinoid receptors.
Table 2 Studies included in the systematic review
Author Year Main outcome Study sample Population SNPs
Association (for main
outcome)





Tsai23 2000 SCZ SCZ patients (127)
Controls (146)
Han Chinese (AAT)n (-)





French rs1049353 (+) for substance
abuse in patients
Krebs25 2002 SCZ; cannabis abuse SCZ cannabis (102)
Non-SCZ cannabis (85)
Controls (89)
French (AAT)n (+) for cannabis-
sensitive SCZ patients


















Continued on next page
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Table 2. (continued )
Author Year Main outcome Study sample Population SNPs
Association (for main
outcome)







(AAT)n (+) for cocaine
addiction
Martinez-Gras5 2006 SCZ; substance abuse SCZ patients (113)
Controls (111)
Spanish (AAT)n (+) for schizophrenia
















Costa Rica (AAT)n (+) for hebephrenic
SCZ










Monteleone30 2010 SCZ; weight gain SCZ patients (83)
Controls (80)
Italian rs1049353 (-)
























Ho31 2011 Cannabis abuse; MRI;
neurocognitive
assessment















Park32 2011 Weight gain
(olanzapine)
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Table 2. (continued )







Schennach34 2012 Treatment response SCZ patients (274)
Controls (427)
German rs1049353 (-)




























































(+) rs6454674 for SCZ
symptoms








(+) all SNPs for MRI
and clinical
psychopathology
BMI = body mass index; SCZ = schizophrenia; MetS = metabolic syndrome; MRI = magnetic resonance imaging; PANSS = Positive and
Negative Syndrome Scale; SNP = single nucleotide polymorphism; TD = tardive dyskinesia; WCST = Wisconsin Card Sorting Test.
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(p = 0.0028). Hebephrenic-type schizophrenia - character-
ized by predominance of negative symptoms such as
blunted affect, disorganized thought, and deterioration of
personality - was associated with significantly increased
frequency of the 9 repeat allele (p = 0.032; odds ratio
[OR] = 2.30; 95% confidence interval [95%CI] 1.91-2.69)
and decreased frequency of the 17 repeat allele (p = 0.011;
OR = 0.208; 95%CI 0.098-0.439). This was the first study
to verify a possible influence of CNR1 gene variants on
disorganized forms of schizophrenia.16
Later studies reported controversial findings regarding
the association between this polymorphism and schizo-
phrenia. Martinez-Gras et al.40 studied possible influ-
ences of the CNR1 gene in schizophrenia by analyzing
the (AAT)n repeat in 113 Spanish patients with schizo-
phrenia and 111 healthy controls. Comparison of allele
frequencies showed significant differences between the
two groups. Allele 4 was overrepresented in controls
(chi-square [w2] = 7.858; degrees of freedom [df] = 1;
p = 0.005), suggesting that this allele could represent the
protective variant of this gene for schizophrenia.40
In an African Caribbean population, Ballon et al.17 did
not find differences in allele or genotype distribution of
the (AAT)n polymorphism between cocaine dependents
with schizophrenia (n=45) and those without schizophre-
nia (n=97), suggesting this polymorphism might not be
associated with the disorder.
Chavarria-Siles et al.29 replicated the findings of Ujike
et al.16 in a population of 244 subjects with a DSM-IV
diagnosis of schizophrenia and 481 family members
recruited from psychiatric hospitals and clinics in the
Central Valley of Costa Rica. The study found a positive
correlation of prominent lifetime scores for disorganiza-
tion and negative symptoms (hebephrenia dimension)
with the (AAT)n polymorphism (multiallelic p = 0.0368).
These findings support the hypothesis that variation in the
CNR1 gene confers risk for a hebephrenic type of
schizophrenia.29 However, this study did not confirm the
association between (AAT)n polymorphism and schizo-
phrenia as a broad phenotype.
Other studies in Caucasian populations did not show any
association of CNR1 gene polymorphisms with occurrence
of schizophrenia. Seifert et al.27 performed an association
study in a sample of 104 German patients with schizo-
phrenia and 140 healthy individuals, analyzing three known
CNR1 polymorphisms (rs6454674, rs1049353, and the
AAT-repeat). No statistically significant differences were
found between the two groups.27
Zammit et al.28 conducted the association study of the
CNR1 gene and schizophrenia with the largest sample to
date. Individuals were recruited from outpatient and
inpatient clinical settings and from volunteer support orga-
nizations in the United Kingdom. Overall, 797 participants
with schizophrenia and 688 healthy controls were geno-
typed for the CNR1 rs1049353 polymorphism. Allele
frequencies were compared between the two groups,
and there was no evidence for any association of this
polymorphism with schizophrenia (OR = 0.97; 95%CI
0.82-1.13). This study also failed to demonstrate any
association between rs1049353 genotypes and various
phenotypes within schizophrenia, such as age at onset.28
Two French studies also examined the allele frequen-
cies of rs1049353 and other SNPs in patients with
schizophrenia and controls. Both failed to demonstrate
any association between the disorder and variations of
CNR1 gene, but found possible influences on treatment
response and comorbidity with drug abuse, as we will
discuss further below.18,24
In an Italian population, two case-control association
studies30,36 reported negative results. While Monteleone
et al.30 investigated only one CNR1 SNP (rs1049353),
Costa et al.36 tested 12 SNPs in the CNR1 gene. After
running multiple comparisons analysis, none of the asso-
ciations remained significant. Another study in 740 un-
affected siblings of 801 patients with psychosis from the
Netherlands and Belgium did not find a significant asso-
ciation between eight CNR1 SNPs and schizotypal
symptoms and signs, though a marginal effect was
observed for rs1049353 (p = 0.044).33
Bae et al.21 carried out a case-control association study
in a Korean population and did not find any association
between three SNPs in the CNR1 gene (rs806376,
rs806368, and rs806366) and schizophrenia.21 A more
recent study conducted in Turkey also found no dif-
ferences in allele frequencies of three SNPs in CNR1
gene (rs6454674, rs806368, and rs1049353), though
the authors reported a significant association between
rs6454674 and schizophrenia symptoms assessed by
the Positive and Negative Syndrome Scale (PANSS) and
Clinical Global Impression Severity Scale (CGI-S).38
Investigating three CNR1 SNPs (rs1049353, rs1535255,
and rs2023239) in a first-episode psychosis cohort of
65 patients, Suárez-Pinilla et al.39 reported a significant
association of the rs2023239 polymorphism with symp-
toms of schizophrenia at 3-year follow-up. Specifically,
T/T patients showed a significant improvement in posi-
tive (F1,61 = 8.76; p = 0.004) and negative symptoms
(F1,61 = 4.51; p = 0.038) compared with T/C patients.
Moreover, a significant association was observed be-
tween the interaction of these three SNPs and positive
symptoms.
In total, of the 16 studies that explored the association
between CNR1 polymorphisms and occurrence of schizo-
phrenia, 15 failed to find a significant association with any
SNP. However, some of the studies reported significant
results for other categories or symptoms, such as an
effect of the (AAT)n polymorphism on hebephrenia16,29
and of rs6454674 on PANSS and CGI-S scores.38 More-
over, a case-only study identified a significant associa-
tion between CNR1 SNPs and positive and negative
symptoms.39
CNR1 gene polymorphisms and comorbidity of
schizophrenia with substance abuse
Substance abuse disorders, particularly cannabis abuse,
are very common among patients with schizophrenia.41
Much research has been carried out in the search for
possible neurobiological pathways and clinical implica-
tions underlying the high prevalence of this comorbid-
ity.42,43 The endocannabinoid system appears as an
interesting target due to its modulatory action and cross-
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talk with the dopaminergic system44; hence, this interac-
tion could influence phenomena such as drug tolerance,
craving, dependence, and relapse.45
A meta-analysis conducted by Benyamina et al.46
analyzed clinical studies regarding CNR1 polymorphisms
and addictive disorders in the general population. They
found that only the (AAT)n polymorphism was significantly
associated with illicit substance dependence in Caucasian
samples, using a risk allele of X 16 repeats. The analysis
also showed a small effect size (OR = 1.55; p = 0.045) with
strong heterogeneity (Q = 19.87; p o 0.01 with I2 = 85%).
This meta-analysis supports a minor implication of CNR1
AAT polymorphism in illicit substance abuse vulnerability,
taking a multifactorial model into account. The same ana-
lysis also explored studies of other CNR1 polymorphisms,
including rs1049353 and rs806379, and did not find a
correlation with alcohol and drug dependence.46
As described above, Ballon et al.17 evaluated the (AAT)n
polymorphism in 97 cocaine dependents without schizo-
phrenia and 45 cocaine dependents with schizophrenia.
They also compared both groups to 88 matched controls
with no personal or family history of psychiatric disorders,
including substance abuse. Although no significant differ-
ence was found between cocaine dependents with and
those without schizophrenia, the frequency of the (AAT)12
repeat allele was increased in both groups of cocaine
dependents vs. controls (cocaine dependents without sch-
izophrenia, 25.3%; cocaine dependents with schizophrenia,
26.7%; controls, 5.7%; p o 0.001). The author concluded
that the (AAT)n polymorphism near the CNR1 gene could
be associated with predisposition to cocaine dependency,
with the same risk for individuals with and those without
schizophrenia.17
Other three studies, all conducted in France, investi-
gated the association between schizophrenia/substance
abuse and CNR1 polymorphisms. Leroy et al.24 found, as
a tendency, a non-significantly lower frequency of the
rs1049353 SNP G-allele in non-substance-abusing pati-
ents with schizophrenia compared to substance-abusing
patients with schizophrenia (69% vs. 81%, p = 0.059).
The GG-genotype was significantly less frequent in non-
substance-abusing than in substance-abusing patients
(48% vs. 69%; w2 = 4.32; df = 1; p = 0.038), the frequency
in the latter being similar to that of controls (65%).24 Later,
the same group investigated another CNR1 polymorphism
and found a significant lack of allele 8 of the (AAT)n re-
peat in ‘‘cannabis-sensitive’’ patients (i.e., patients with
schizophrenia whose symptoms had been triggered or
exacerbated in a context of cannabis consumption or mis-
use) when compared to the remaining patients (p = 0.0028)
or to controls (p = 0.014).25 There were no differences in
allele or genotype distributions between the whole group of
patients with schizophrenia and controls. A third group of
addicted patients without schizophrenia were not different
from controls (p = 0.13).47 Finally, in an independent study,
Hamdani et al.18 did not replicate this association between
rs1049353 and substance abuse.
As mentioned, Martinez-Gras et al.40 observed an
association between the (AAT)n polymorphism and schi-
zophrenia; however, in the same study, they did not find
significant differences with respect to substance abuse
when comparing 68 patients with schizophrenia and sub-
stance abuse and 45 without substance abuse. Zammit
et al.,28 in a larger sample, failed to find a significant effect
of rs1049353 genotype on schizophrenia between those
who did not use cannabis and those who did. However,
van Winkel et al.,33 evaluating 740 unaffected siblings of
patients with schizophrenia, observed an interaction
between CNR1 SNPs rs806379 and rs806308 and earlier
cannabis use, using positive schizotypy as the outcome,
though the association was not significant after Bonferroni
correction for multiple comparisons.
Evaluating other phenotypes, such as magnetic reso-
nance imaging (MRI) findings and neurocognition, Martinez-
Gras26 compared substance abusers and non-substance
abusers with schizophrenia and reported that patients
with CNR1 short alleles (from [AAT]n polymorphism) who
abused substances exhibited significantly higher scores on
the negative PANSS scale (p = 0.022) and completed less
categories on the Wisconsin Card Sorting Test (WCST)
(p = 0.039) than patients who did not abuse substances.
Another study genotyped 235 patients with schizo-
phrenia and investigated 12 SNPs that account for most
of the genetic variability of the CB1 coding region. Geno-
types were correlated with high-resolution anatomic brain
MRI and cognitive assessment. Comorbidity with DSM-IV
diagnosis of cannabis abuse and dependence, taken
together, was found in % of the sample. There were no
differences in allele frequencies of any of the analyzed
SNPs, including rs1049353, between patients with or
without cannabis abuse/dependence. However, there
were significant rs12720071 genotype-by-marijuana use
interaction effects on white matter (WM) volumes and neu-
rocognitive impairment. Notably, carriers of the rs12720071
G-allele with cannabis abuse/dependence had the smallest
mean parietal WM volumes (p = 0.05) and the worst
cognitive performance on a Problem Solving Test. The
authors concluded that heavy cannabis use in the context
of specific CNR1 genotypes might contribute to greater
WM volume deficits and cognitive impairment, suggestive
of gene-environment interactions conferring phenotypic
abnormalities in schizophrenia.31
A more recent study investigated three CNR1 SNPs
(rs1049353, rs1535255, and rs2023239) to verify their
association with brain volumes, body mass index (BMI),
or psychopathological scores in 65 first-episode psy-
chosis patients.39 Data were obtained at the onset of
first episode of psychosis and at 3-year follow-up. For
those who were not cannabis users, the rs1535255 and
rs2023239 polymorphisms had effects on lateral ventricle
(LV) and LV and WM volume, respectively. Moreover, a
significant interaction of the rs1049353 polymorphism
with cannabis consumption on BMI was observed.
In total, 10 studies investigated CNR1 polymorphisms
and substance abuse in individuals with schizophrenia.
Six of these reported significant results. One associated
the (AAT)n polymorphism with cocaine addiction17 and
another with cannabis-sensitive schizophrenia.25 A third
study reported a significant effect of the rs1049353 SNP
and substance abuse in patients with schizophrenia.24
Moreover, three studies identified significant interaction
effects on other phenotypes: Martinez-Gras26 observed
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an (AAT)n genotype-by-substance use interaction on
psychopathology and neurocognition scores, Ho et al.31
reported a significant rs12720071 genotype-by-marijuana
use interaction on MRI findings and neurocognition mea-
sures, and Suárez-Pinilla39 identified a rs1049353 geno-
type-by-marijuana use interaction on BMI and rs1535255
and rs2023239 genotypes-by-marijuana use interaction
on MRI findings.
CNR1 gene polymorphisms and pharmacological
treatment of schizophrenia
In this section, we will discuss studies that investigated
possible influences of CNR1 gene polymorphisms on
refractoriness to antipsychotic therapy and some adverse
effects of these agents, including extrapyramidal symp-
toms and induced weight gain. This field clearly exem-
plifies the heterogeneity of schizophrenia in terms of
treatment efficacy and tolerability. The future of psycho-
pharmacology can be defined by the possibility of per-
sonalized treatment, in which clinicians could identify
patients who might respond better to a certain drug or
experience fewer adverse effects. This is crucial in a
chronic disorder like schizophrenia, and could predict
better prognosis and less functional impairment. In this
sense, the field of pharmacogenomics seeks to identify
biological markers for optimal treatment.48 The dopami-
nergic and serotoninergic systems have been the main
targets of research into genetic determinants of schizo-
phrenia refractoriness, but other systems (e.g., glutama-
tergic and endocannabinoid) are increasingly being
studied. Authors have investigated possible influences of
the CNR1 gene on treatment response and found con-
troversial results. The first study to investigate this hypoth-
esis was conducted by Leroy et al.24 in 102 patients with
schizophrenia or schizoaffective disorder, 26 of whom were
treatment-refractory. The authors analyzed the rs1049353
SNP and found that treatment-responding patients did not
differ significantly from refractory patients with regard to
allele frequency (w2 = 0.03; df = 1; p = 0.86) or genotype
distribution (w2 = 2.69; df = 2; p = 0.26).24
Another study, also conducted in a French population
sample by Hamdani et al.,18 recruited 133 patients with
schizophrenia from two hospitals in the Paris area. All
were treated with atypical antipsychotics (including clo-
zapine) for at least 4 weeks at appropriate dosages.
Four CNR1 SNPs were analyzed: rs806368, rs1049353,
rs806379, and rs806380. The G-allele of rs1049353 was
found in excess in patients with schizophrenia refractory
to atypical antipsychotics compared with responders
(85.6% vs. 71.6% ; w2 = 7.420; p = 0.006). This obser-
vation was independent of the geographic region of
patient origin. The G-allele appeared to exert a dose-
related influence on therapeutic response, increasing the
risk of refractoriness in up to 76% of GG homozygous
subjects. The association appeared to be specific of the
genetic block where the rs1049353 polymorphism is
located, because the three other SNPs encompassing
the CNR1 gene, but with no linkage disequilibrium (LD),
showed no association with treatment refractoriness.18
In contrast to the previous study,24 these findings suggest
that the G-allele of rs1049353 could be a pharmacoge-
netic factor for response to atypical antipsychotic drugs.
In a recent letter to the editor, Schennach et al.34 repor-
ted having found no significant association between
rs1049353 and early improvement or clinical response.
Other authors also looked at influences of the CNR1
gene on the development of adverse effects to antipsycho-
tic treatment. Considering that CNR1 has been implicated
in the regulation of feeding behavior and body weight,49
Tiwari et al.19 investigated the possible association of
CNR1 polymorphisms with antipsychotic-induced weight
gain. This study analyzed 20 SNPs of the CNR1 gene
in a sample of 183 patients from three different sites in
Germany and the U.S. Patients were treated with typical
(haloperidol) and atypical (risperidone, olanzapine, and
clozapine) agents and evaluated for antipsychotic-induced
weight gain for up to 14 weeks. The results showed that the
rs806378 polymorphism was associated with weight gain in
patients of European ancestry treated with clozapine or
olanzapine. T-allele carriers (CT + TT) had an additional
weight gain of approximately 2.2 kg than patients homo-
zygous for the CC genotype (4.3363.89 kg vs. 2.216
4.51 kg; p = 0.022). The authors concluded that CNR1may
be associated with antipsychotic-induced weight gain in
patients with chronic schizophrenia, but these results still
need to be replicated in larger sample sets.19
Another study, conducted in Korea with a small sample
(n=78), found no significant association between CNR1
polymorphisms (rs1049353, rs806368, and rs4707436)
and olanzapine-induced weight gain in patients with
chronic schizophrenia.32 Likewise, an Italian study found
no association between CNR1 polymorphism rs1049353
and antipsychotic-induced weight gain.30
Besides weight gain, some studies have linked the
CNR1 gene to obesity and various metabolic parame-
ters.50,51 Yu et al.37 investigated whether genetic variation
in CNR1 was associated with the metabolic syndrome
(MetS). A total of 407 patients with schizophrenia,
schizoaffective disorder, and schizophreniform disorder
were compared regarding occurrence of MetS (n=143
with MetS and n=264 without MetS). Seven CNR1 SNPs
were investigated (rs6454674, rs6928499, rs806379,
rs1535355, rs806377, rs1049353, and rs3023239), and
the minor alleles of rs6928499 (p = 0.006), rs1535255
(p = 0.006), and rs2023239 (p = 0.001) were significantly
associated with lower risk of MetS. Further analysis
revealed that this lower risk was attributable mainly to
differences in HDL and fasting glucose.37
Regarding extrapyramidal side effects, Tiwari et al.35
evaluated the occurrence of tardive dyskinesia (TD) in a
sample of 191 patients of European ancestry with schi-
zophrenia (74 with TD). The authors analyzed 20 SNPs
covering the CNR1 gene and found significant genotype
and allele (p = 0.012) associations with the rs806374
(T 4 C) polymorphism. CC genotype carriers were more
likely to be TD-positive (CC vs. TT + TC, OR = 3.4 [1.5-
7.8]; p = 0.003). These results point toward a possible role
of the CNR1 gene in the development of TD. However,
the authors stress that these observations were marginal
after correcting for multiple testing, and need to be
replicated in a larger sample.35
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A total of eight studies included in this review explored
the association between CNR1 polymorphisms and phar-
macological treatment of schizophrenia. Three of these
investigated treatment response, and only one observed
a significant effect.18 Three studies investigated antipsy-
chotic-induced weight gain, and Tiwari et al.19 reported a
positive association between rs806378 and weight gain in
a subsample of patients of European ancestry treated
with clozapine or olanzapine.19 Finally, one study investi-
gated the association of CNR1 SNPs with MetS, and
another investigated its association with TD; both repor-
ted significant results.
Discussion
The (AAT)n trinucleotide polymorphism was associated
with schizophrenia, particularly the hebephrenic subtype,
in several16,29,40 but not all studies included in this review.
The same pattern was found for the rs1049353 SNP,
which correlated positively with treatment refractoriness in
a single study.18 Even in those studies, the authors did
not establish how genetic variants could exert effects on
disorder phenotype. The polymorphisms that were inves-
tigated are not capable of substituting amino acids and
changing protein structure, and have not been found to
alter mRNA expression or disrupt transcription at intronic
promoter regions. Hence, the main possible explanation
for these findings is the LD mechanism. Authors suggest
that the tested variants could be in LD with another
functional SNP along the CNR1 gene, and that haplotype
analyses should be well measured in further studies.
In previous research, CNR1 variants have been asso-
ciated with addictive disorders such as alcohol depen-
dence and drug use.52,53 In a meta-analysis,46 only the
(AAT)n polymorphism showed a significant association
with illicit substance dependence in Caucasian popula-
tion samples, but with a small effect size (OR = 1.55;
p = 0.045). These data are in agreement with Ballon
et al.,17 who concluded that the (AAT)n polymorphism near
the CNR1 gene could be associated with predisposition
to cocaine dependency, with the same risk for patients with
and without schizophrenia. As pointed out by Martinez-
Gras,26 the presence of CNR1 short alleles was asso-
ciated with worse cognitive performance among substance
abusers with schizophrenia. Based on these studies, we
speculate that genetic variants involving the CNR1 gene
could be reflected by neurobiological dysfunctions in
the endocannabinoid system. Given the neuromodulatory
nature of this system, acting on dopaminergic and GABAer-
gic molecular pathways, those variants could influence the
pathophysiology of psychosis, brain reward processes, and
vulnerability to addictive disorders.54,55
Finally, gene-environment approaches integrate the
evidence showing that CNR1 gene polymorphisms and
cannabis misuse could lead to brain abnormalities (WM
volume reductions) and cognitive deficits in schizophre-
nia.31 This modern reasoning directs the future of re-
search in this field, but is still far from a final conclusion.
Several gaps, such as differences in genetic ancestry
among study populations, phenotypic variations of schi-
zophrenia, and the heterogeneity of drug compounds
(e.g., differential biological actions of THC and cannabi-
diol), should be better understood.55
Although our search for the systematic review was
very restrictive, we may have failed to include some eligi-
ble studies, such as genome-wide association studies
(GWAS). These studies probably would present negative
results regarding the CNR1 gene, as they were not
retrieved in our search. Searching for studies on schizo-
phrenia in the GWAS catalog (https://www.ebi.ac.uk/
gwas/) in June 2015, we found 45 studies with schizo-
phrenia or response to treatment or substance depen-
dence as outcome. Of these, none reported a significant
association with CNR1 polymorphisms.
Studies on this gene are very heterogenous, reflecting
the bias on investigating genotype associations using the
candidate gene approach. The conflicting findings of this
review, in part attributable to small sample sizes, do not
allow us to reach a conclusion regarding the real influ-
ences of CNR1 SNPs on the pathophysiology of schizo-
phrenia. Moreover, some unpublished data (including ours
reported herein) might not have been accepted for publi-
cation, reflecting publication bias. However, we included the
grey literature, such as meeting abstracts and letters.
In conclusion, our systematic review on potential asso-
ciations of CNR1 polymorphisms with schizophrenia and
its subphenotypes revealed conflicting data, with results
tending towards a negative association. We also tested
some CNR1 SNPs on a sample of Brazilian subjects and
did not find a significant association. Further studies should
also go beyond genes that encode brain receptors and
investigate the genetic basis of endocannabinoid system
enzymes (e.g., fatty acid amide hydrolase), endogenous
ligands (anandamide), and transporters. GWAS with large
samples are revealing more loci associated to schizo-
phrenia, which may finally allow us to fully understand the
role of endocannabinoid system malfunctioning in the
pathophysiology of schizophrenia and other psychiatric
disorders.
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